The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1031
July 17, 1998
View Complete Issue         Table of Contents 2019 
Platelet-Derived Growth Factor for Diabetic Ulcers
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Platelet-Derived Growth Factor for Diabetic Ulcers
July 17, 1998 (Issue: 1031)
Becaplermin (be kap' ler min; Regranex - Ortho-McNeil), a 0.01% topical gel formulation of recombinant human platelet-derived growth factor (rhPDGF), was recently approved by the FDA for adjunctive treatment of diabetic ulcers of the lower...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Platelet-Derived Growth Factor for Diabetic Ulcers
Article code: 1031b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.